Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Probiotics offer little in terms of GI symptoms in systemic sclerosis

06 Jun 2019

Treatment with probiotics falls short of improving gastrointestinal (GI) symptoms in patients with systemic sclerosis (SSc), a study has shown.

The study randomized 73 SSc patients with a moderate–severe total score on the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA GIT 2.0) instrument to receive a daily dose of probiotics (Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus and Bifidobacterium lactis, 109 colony-forming units per capsule; n=37) or placebo (n=36) for 8 weeks.

After 8 weeks of treatment, the primary outcome of change in UCLA GIT 2.0 total score did not significantly differ between the two treatment groups.

However, probiotics treatment produced a significant decrease in the proportion of Th17 cells compared with placebo (p=0.003). There was no between-group difference observed in the proportion of Th1, Th2 and regulatory T cells or in the Health Assessment Questionnaire-Disability Index (HAQ-DI) score.

Although probiotics did not improve GI symptoms in SSc patients, the improvement in Th17 cell levels suggests that the treatment exerts an immunomodulatory effect on SSc, researchers pointed out.

SSc is a multisystem connective tissue disorder of unknown aetiology, and the GI tract is affected in the vast majority (90 percent) of patients. Gut involvement—with symptoms ranging from gastro-oesophageal reflux to faecal incontinence—is the leading cause of morbidity and the third most common cause of mortality in patients with SSc. [Rheumatology 2019;49:1770-1775]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.